Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Chief Financial Officer | June 28, 2024 | July 01, 2024 |
| GI DYNAMICS, INC.NONE · Entity 141502 | CFO and Secretary | March 09, 2021 | March 11, 2021 |
| ICAD INCICAD · Entity 77446 | CHIEF FINANCIAL OFFICER | January 10, 2022 | January 18, 2022 |
| Ovid Therapeutics Inc.OVID · Entity 5411 | Chief Financial Officer | July 06, 2026 | July 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERO THERAPEUTICS HOLDINGS, INC.
Report date June 28, 2024 · Filed July 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2034-06-28 | Direct | 100,000 |
Reported balance
After 2024-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 100,000 · Balance 100,000 F1: All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date.
GI DYNAMICS, INC.
Report date March 09, 2021 · Filed March 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-09-19 | Direct | 0 |
Reported balance
After 2021-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-09 · Disposition to issuer · Disposed 385,226 · Balance 0 F2: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms and conditions of a stock option cancellation agreement entered into on March 9, 2021, which cancellation is to be deemed effective as of December 31, 2020. F1: The option provided for vesting over a four (4) year period, with one quarter (1/4) of the shares subject to the Option vesting on the one (1) year anniversary of the transaction date, and the remaining shares vesting on a quarterly basis over the following three (3) years of continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option provided for vesting over a four (4) year period, with one quarter (1/4) of the shares subject to the Option vesting on the one (1) year anniversary of the transaction date, and the remaining shares vesting on a quarterly basis over the following three (3) years of continuous service.
F2: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms and conditions of a stock option cancellation agreement entered into on March 9, 2021, which cancellation is to be deemed effective as of December 31, 2020.
ICAD INC
Report date January 10, 2022 · Filed January 18, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.24 · Expires 2032-01-10 | Direct | 150,000 |
Reported balance
After 2022-01-10 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-01-10 · Grant · Acquired 75,000 · Balance 150,000 F1: Represents options to purchase shares of common stock granted to Reporting Person pursuant to the Company's 2016 Stock Incentive Plan, as amended. F2: The shares underlying the option vest annually over a three-year period commencing one year from January 10, 2022, the date the award was approved by the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock granted to Reporting Person pursuant to the Company's 2016 Stock Incentive Plan, as amended.
F2: The shares underlying the option vest annually over a three-year period commencing one year from January 10, 2022, the date the award was approved by the Company's Board of Directors.
Ovid Therapeutics Inc.
Report date July 06, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,375 |
Reported balance
After 2026-07-06 transaction · row 1
1 source rowRow 1 · 2026-07-06 · Grant · Acquired 50,000 · Balance 94,375 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date. F2: Each RSU represents a contingent right to receive one share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date.
F2: Each RSU represents a contingent right to receive one share of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 8, 2026 20:31 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001779359-26-000004 · form4-07082026_080741.xml · nonDerivative · entry 1 Carter Charles Ross · CIK 0001779359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,375 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:01 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001213900-24-057868 · ownership.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-06-28 F1 · derivative.exercise_date: All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 01:26 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 395,387 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001213900-24-026818 · ownership.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,387 Underlying: Common Stock · 395,387 shares Expires 2034-03-24 F1 · derivative.exercise_date: The shares underlying this option vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 14:41 UTC | ICAD INC ICAD · Entity 77446 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $6.24 Strike: $6.24 | $468,000.00 |
DisclosureSEC source: 0000899243-22-001718 · doc4.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 75,000 shares Expires 2032-01-10 F1 · shares: Represents options to purchase shares of common stock granted to Reporting Person pursuant to the Company's 2016 Stock Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying the option vest annually over a three-year period commencing one year from January 10, 2022, the date the award was approved by the Company's Board of Directors. Read SEC document |
| January 10, 2022 Filed Jan 18, 2022 06:15 UTC Amendment | ICAD INC ICAD · Entity 77446 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0000899243-22-002067 · doc4a.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 75,000 shares Expires 2032-01-10 F1 · shares: Represents options to purchase shares of common stock granted to Reporting Person pursuant to the Company's 2016 Stock Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying the option vest annually over a three-year period commencing one year from January 10, 2022, the date the award was approved by the Company's Board of Directors. Read SEC document |
| December 08, 2021 Filed Dec 15, 2021 16:06 UTC | ICAD INC ICAD · Entity 77446 | PurchaseCommon Stock | 7,000 | $7.05 | $49,350.00 |
DisclosureSEC source: 0000899243-21-048350 · doc4.xml · nonDerivative · entry 1 Carter Charles Ross · CIK 0001779359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | ICAD INC ICAD · Entity 77446 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $14.14 | $0.00 |
DisclosureSEC source: 0000899243-21-031620 · doc4.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-08-02 F1 · shares: Represents options to purchase shares of common stock granted to the Report Person pursuant to the Company's 2016 Stock Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying the option vest annually over a three-year period commencing one year from August 2, 2021, the date the award was approved by the Company's Board of Directors. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:05 UTC | GI DYNAMICS, INC. NONE · Entity 141502 | Disposition to issuerStock Option (right to buy) · Derivative | 385,226 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001213900-21-014887 · ownership.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 385,226 shares Expires 2029-09-19 F2 · price: The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms and conditions of a stock option cancellation agreement entered into on March 9, 2021, which cancellation is to be deemed effective as of December 31, 2020. F1 · derivative.exercise_date: The option provided for vesting over a four (4) year period, with one quarter (1/4) of the shares subject to the Option vesting on the one (1) year anniversary of the transaction date, and the remaining shares vesting on a quarterly basis over the following three (3) years of continuous service. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 19:43 UTC | GI DYNAMICS, INC. ASX:GID · Entity 141502 | GrantStock Option (right to buy) · Derivative | 385,226 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000899243-19-024042 · doc4.xml · derivative · entry 1 Carter Charles Ross · CIK 0001779359 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,226 Underlying: Common Stock · 385,226 shares Expires 2029-09-19 F1 · derivative.exercise_date: The option will vest over a four (4) year period, with one quarter (1/4) of the shares subject to the Option vesting on the one (1) year anniversary of the transaction date, and the remaining shares vesting on a quarterly basis over the following three (3) years of continuous service, provided that you are providing services to the Company as an employee or consultant on such vesting dates (no vesting will occur following the termination of employment or consulting services). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.